Rapport Therapeutics Insider Trims Position Amid Clinical Progress and Stock Surge

Third Rock Ventures V, L.P., a 10% owner of Rapport Therapeutics (NASDAQ: RAPP), has reduced its stake in the Boston-based biotechnology company. According to an SEC Form 4 filing, the venture firm sold 426,005 shares on April 17, 2026, for a total value of approximately $17.18 million. The sale represents roughly 5.3% of Third Rock's direct common stock holdings. The transaction occurred after a period of significant growth, with RAPP shares surging over 230% over the past year. Despite the sale, Third Rock maintains a substantial position, with 969,218 shares still held indirectly. The divestment follows positive Phase 2a results for the company's lead candidate, RAP-219. The trial demonstrated a 90% median reduction in clinical seizures during a portion of the follow-up period. Notably, the drug's 22-day half-life contributed to durable effects that persisted even after dosing ceased. Rapport is now shifting toward late-stage development, with two Phase 3 trials scheduled to commence in the second quarter of 2026. The company continues to expand its pipeline to include studies for bipolar mania and other neurological conditions. Market analysts view the insider sale as a strategic trimming of a position into strength rather than a shift in the underlying investment thesis. Investors are now focusing on the upcoming Phase 3 catalysts as the primary drivers for future valuation.